Vaccine Development Monoclonal Antibodies Directed Against Signal Peptide

Hochman Jacob, HUJI, Faculty of Science, The Alexander Silberman Institute for Life Sciences


Our Overall Objective is to generate monoclonal antibodies directed against signal peptide (SP) and envelope proteins of COVID-19 for subsequent immune therapy and putative vaccination in the clinical setting.

Our Approach is to use synthetic, and/or recombinant peptides comprising the SP and envelope of the virus for the immunization of mice. Mice with positive sera will be used for the generation of the monoclonal antibodies. These will be tested against the different peptides for validation. Positive monoclonals will then be sent out to an authorized laboratory for validation against COVID-19, either as purified antibodies or alternatively as antibody-drug conjugates. Positive monoclonals after this step, will be humanized for further studies in the clinic. A positive immune response may also suggest that the antigens used for immunization could also be applied as putative vaccines.

Our Experience: We have a long standing experience with the generation and application of monoclonal antibodies against cancer cells. Specifically, we have generated such antibodies against Signal peptide epitopes of a virus (MMTV) that is associated with human breast cancer. These antibodies have been used for both diagnosis of MMTV-associated human breast cancer as well as for inhibition of breast cancer tumors (that contain the virus) in mice.

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
Contact ME:
All projects by:Hochman Jacob (2)